Nuformix PLC Letter to shareholders re: Dr Anne Brindley
July 22 2021 - 2:00AM
RNS Non-Regulatory
TIDMNFX
Nuformix PLC
22 July 2021
REACH - Non-regulatory announcement
Nuformix plc
("Nuformix" or the "Company")
Letter to shareholders re: Dr Anne Brindley
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that further to the RNS issued yesterday on
the departure of Dr Anne Brindley as CEO, the Company has issued a
letter to shareholders. The letter can be viewed here:
https://nuformix.com/document-center/
Enquiries:
Nuformix plc via Walbrook
Dr Alastair Riddell, Non-Executive
Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44 (0)20
7933 87 80
Anna Dunphy / Paul McManus / Tel: +44 (0)7876 741 001 / +44
Kiki Zaccagnini (0)7980 541 893
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEFLFLFDLEBBB
(END) Dow Jones Newswires
July 22, 2021 02:00 ET (06:00 GMT)
Levrett (LSE:LVRT)
Historical Stock Chart
From Apr 2024 to May 2024
Levrett (LSE:LVRT)
Historical Stock Chart
From May 2023 to May 2024